These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 14719493)

  • 21. Developing drugs for developing countries.
    Ridley DB; Grabowski HG; Moe JL
    Health Aff (Millwood); 2006; 25(2):313-24. PubMed ID: 16522573
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmaceuticals and Medical Devices: Cost Savings.
    Steiner DJ;
    Issue Brief Health Policy Track Serv; 2015 Dec; ():1-31. PubMed ID: 27116794
    [No Abstract]   [Full Text] [Related]  

  • 23. Should terminally ill patients have access to phase I drugs?
    Bristol N
    Lancet; 2007 Mar; 369(9564):815-6. PubMed ID: 17366691
    [No Abstract]   [Full Text] [Related]  

  • 24. A centralized system to access acute healthcare services: the pros and cons.
    Brown S
    Healthc Manage Forum; 2005; 18(2):34-7. PubMed ID: 16119385
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of new pharmaceutical agents on pharmacy budgets.
    Kozma CM
    Manag Care Interface; 1999 Jan; 12(1):77-8. PubMed ID: 10345243
    [No Abstract]   [Full Text] [Related]  

  • 26. Pharmac dogma.
    Douglas B
    N Z Med J; 2007 Feb; 120(1249):U2430. PubMed ID: 17308566
    [No Abstract]   [Full Text] [Related]  

  • 27. Drug reimbursement policies in Canada--need for improved access to critical therapies.
    LeLorier J; Bell A; Bougher DJ; Cox JL; Turpie AG
    Ann Pharmacother; 2008 Jun; 42(6):869-73. PubMed ID: 18477735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Canadian developments. Minister announces new drug approval initiatives.
    Garmaise D
    HIV AIDS Policy Law Rev; 2005 Aug; 10(2):21-2. PubMed ID: 16370027
    [No Abstract]   [Full Text] [Related]  

  • 29. [Medical problems and risks of switching drugs according to legal requirements of drug discount contracts in Germany].
    Pruszydlo MG; Quinzler R; Kaltschmidt J; Haefeli WE
    Dtsch Med Wochenschr; 2008 Jul; 133(27):1423-8. PubMed ID: 18592450
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rationing health care in Canada.
    Brown MG
    Ann Health Law; 1993; 2():101-19. PubMed ID: 10139963
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A study in futility: Abigail Alliance for Better Access to Developmental Drugs will not expand access to experimental drugs for the terminally ill.
    Ochs A
    Seton Hall Law Rev; 2009; 39(2):559-603. PubMed ID: 19462540
    [No Abstract]   [Full Text] [Related]  

  • 32. The response to health care reform by the pharmaceutical industry.
    Krulwich AS
    Food Drug Law J; 1995; 50(1):1-22. PubMed ID: 10342983
    [No Abstract]   [Full Text] [Related]  

  • 33. Approval process and access to prescription drugs in Canada.
    Marra CA; Lynd LD; Anis AH; Esdaile JM
    Arthritis Rheum; 2006 Feb; 55(1):9-11. PubMed ID: 16463404
    [No Abstract]   [Full Text] [Related]  

  • 34. Breadth, Depth and Agreement among Provincial Formularies in Canada.
    Morgan S; Hanley G; Raymond C; Blais R
    Healthc Policy; 2009 May; 4(4):e162-84. PubMed ID: 20436800
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Provincial drug plan officials' views of the Canadian drug safety system.
    Lexchin J; Wiktorowicz M; Moscou K; Eggertson L
    J Health Polit Policy Law; 2013 Jun; 38(3):545-71. PubMed ID: 23418364
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Biosimilars - Potential, risks and open questions].
    Dtsch Med Wochenschr; 2014 Jan; 139(1-2):12-3. PubMed ID: 24551883
    [No Abstract]   [Full Text] [Related]  

  • 37. The terminally ill, access to investigational drugs, and FDA rules.
    Blake V
    Virtual Mentor; 2013 Aug; 15(8):687-91. PubMed ID: 23937785
    [No Abstract]   [Full Text] [Related]  

  • 38. Speeding up access to new drugs.
    Hawkes N
    BMJ; 2012 Feb; 344():e999. PubMed ID: 22344456
    [No Abstract]   [Full Text] [Related]  

  • 39. Access to biologic therapies in Canada for children with juvenile idiopathic arthritis.
    Leblanc CM; Lang B; Bencivenga A; Chetaille AL; Dancey P; Dent P; Miettunen P; Oen K; Rosenberg A; Roth J; Scuccimarri R; Tse SM; Benseler S; Cabral DA; Campillo S; Chédeville G; Duffy CM; Duffy KW; Haddad E; Huber AM; Laxer R; Levy D; Johnson N; Ramsey S; Shiff N; Schmeling H; Schneider R; Stringer E; Yeung RS; Tucker LB
    J Rheumatol; 2012 Sep; 39(9):1875-9. PubMed ID: 22859344
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Access to medicines and global health: will Canada lead or flounder?
    Orbinski J
    CMAJ; 2004 Jan; 170(2):224-6. PubMed ID: 14734437
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.